IgM Flare in Anti-MAG Neuropathy After Rituximab Treatment
Author Information
Author(s): Siconolfi Giovanni, Vitali Francesca, Sciarrone Maria Ausilia, Ardito Michelangelo, Guglielmino Valeria, Romano Angela, Granata Giuseppe, Silvestri Gabriella, Luigetti Marco
Primary Institution: Dipartimento Di Neuroscienze, Università Cattolica del Sacro Cuore, Sede Di Roma, Italy
Hypothesis
What is the prevalence and impact of acute worsening of symptoms in patients with anti-MAG neuropathy following rituximab treatment?
Conclusion
Acute clinical deterioration can occur after rituximab treatment in patients with anti-MAG neuropathy, but further research is needed to understand its prevalence and predictors.
Supporting Evidence
- 62% of patients achieved full recovery after additional treatment.
- Plasmapheresis led to complete recovery in all four patients who received it.
- Many patients improved after stopping rituximab treatment without further intervention.
Takeaway
Some people with a nerve problem called anti-MAG neuropathy can get worse after taking a medicine called rituximab, but many get better again with other treatments.
Methodology
A systematic review of case reports and series was conducted, focusing on patients with anti-MAG neuropathy who experienced acute worsening after rituximab treatment.
Limitations
The study did not assess the true prevalence of acute worsening after rituximab treatment.
Participant Demographics
Most patients were male (53%) with a mean age of 68 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website